ABIVAX

Perfil da empresa

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Descrição disponível em inglês.

Dados da empresa

Setor

Saúde

Indústria

Biotechnology

País

França

Sede

7-11 Boulevard Haussmann, 75009, Paris

Funcionários

98

Listagem

ABVX · Euronext Paris

Moeda

EUR

ISIN

FR0012333284

Site

abivax.com